Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

Diabetes Mellitus, Type 2
Diabetic Peripheral Neuropathy


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jan 2025 Aug 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

Intervention Arm Group : CagriSema;

Intervention Type : DRUG
Intervention Description : Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

Intervention Arm Group : Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Royal Hallamshire Hospital
    Sheffield
    S10 2JF
  • Aintree University Hospital
    Liverpool
    L9 7AL
  • St Pancras Clinical Research
    London
    EC2Y 8EA
  • Tameside General Hospital
    Ashton-under-Lyne
    Greater Manchester
    OL6 9RW
  • Ipswich Hospital - Diabetes
    Ipswich
    IP4 5PD
  • Kings College Hospital - Renal
    London
    SW9 8RR
  • Manchester Royal Infirmary - Diabetes
    Manchester
    M13 9WL


The study is sponsored by Novo Nordisk A/S





We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT06797869
Last updated 04 December 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.